Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study
Sofosbuvir taken before or after liver transplant reduces hepatitis C recurrence
Simeprevir + sofosbuvir produces high sustained response rates for hard-to-treat patients in COSMOS trial
High response rates with telaprevir triple therapy for HIV-positive men with acute hepatitis C
In ELECTRON trial, 100% of hard-to-treat patients cured with sofosbuvir/ledipasvir plus ribavirin or GS-9669
HCV reinfection is common among HIV-positive gay men in Europe
Ensuring good-quality HIV care in Europe: where can we improve?
New EACS treatment guidelines strike balance between individual choice and public health, say writers
New drugs will bring revolution in hepatitis C treatment
